For Healthcare Professionals

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

clipboard-pencil

About the study

This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Key Inclusion Criteria:

  1. Aged ≥18 years
  2. Relapsed or refractory, histologically confirmed large B-cell lymphoma.
  3. Must have relapsed or refractory diseae after last therapy.
  4. For enrollment in cohort 1, patients must have previously received a CD19-directed CAR T-cell therapy
  5. For enrollment in cohort 3, patients must have received at least two prior lines of therapy including a bispecific T-cel engaging antibody therapy.
  6. Must have at least one radiographically measurable lesion.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  8. Adequate hematological, renal, and liver function
  9. Willing and able to remain within 1 hour of the treating center for at least 4 weeks after infusion.

EXCLUSION CRITERIA

Key Exclusion Criteria:

  1. Clinically significant concurrent medical illness
  2. Active fungal, bacterial, viral or other infection.
  3. Prior allogeneic stem cell transplant or allogeneic cell therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall (650) 499-8952Email iconEmail Study Center

Study Details


Contition

Cancer,Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Age

18+

Phase

PHASE2

Participants Needed

123

Est. Completion Date

Dec 13, 2026

Treatment Type

INTERVENTIONAL


Sponsor

CARGO Therapeutics

ClinicalTrials.gov NCT Identifier

NCT05972720

Study Number

CRG-022-101

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.